A new post-grant review at the Patent Trial and Appeal Board could be one to watch for companies operating in the dental implant and broader medical-device space. On August 11, 2026, Straumann USA, LLC filed PGR2026-00070, asking the PTAB to review a recently issued patent.

A new post-grant review petition has been filed at the Patent Trial and Appeal Board against Straumann USA, LLC, opening what could become a closely watched dispute for practitioners in the dental and medical-device patent space. The proceeding, PGR2026-00070, was filed on August 11, 2026. View full case on Docket Alarm

At this early stage, the PTAB docket identifies Straumann USA, LLC in the case caption, but practitioners will want to watch the filing record closely to confirm the specific patent number at issue, the named petitioner, and the precise claims challenged once the petition and related papers are available through the docket.

A new post-grant review at the Patent Trial and Appeal Board could be worth close attention for companies operating in the dental implant and medical device space. In PGR2026-00070, filed on August 11, 2026, the proceeding is captioned Straumann USA, LLC, signaling a challenge to a recently issued patent associated with one of the best-known names in dental technology.

At this stage, the docket entry identifies the matter by party name and PTAB number, but practitioners will want to watch for the petition and related filings to clarify the specific patent claims at issue, the identity of the petitioner, and the precise invalidity theories being advanced.

The FTC has secured what it says is the largest civil penalty ever obtained for a Hart-Scott-Rodino filing failure: a combined $12 million settlement with Edwards Lifesciences and Genesis MedTech over the acquisition of JC Medical. According to the agency, the companies structured the transaction to avoid premerger notification and waiting-period requirements under the HSR Act, prompting an enforcement action filed in the U.S. District Court for the District of Columbia by the DOJ on the FTC’s behalf.

That headline number matters.

ResMed Corp. has been named in a new inter partes review, IPR2026-00341, filed on June 12, 2026, before the Patent Trial and Appeal Board. While the newly filed docket entry identifies the proceeding by the company name, practitioners will want to watch closely as the petition develops and the challenged patent, claims at issue, and prior-art combinations come into sharper focus through the institution briefing.

At this stage, the publicly available case caption signals that a patent associated with ResMed’s portfolio is being challenged at the PTAB.

A new inter partes review has been filed at the Patent Trial and Appeal Board against ResMed Corp., opening another front in the increasingly important fight over respiratory and sleep-therapy technology. The petition, docketed as IPR2026-00341 and filed June 12, 2026, places at issue the validity of a ResMed patent before the PTAB, where petitioners can seek cancellation of issued patent claims based on prior art patents and printed publications.

At this early stage, the publicly available docket information identifies the proceeding as Resmed Corp., but does not yet provide the full set of petition details typically most relevant to practitioners, including the patent number, the petitioner’s identity, and the specific prior-art combinations asserted.

Another PTAB proceeding has been filed against ResMed, with IPR2026-00341 entering the Patent Trial and Appeal Board on June 12, 2026. The petition places one of ResMed’s patents under inter partes review, opening a new front in what could become an important dispute for companies operating in the sleep-disorder and respiratory-device space.

At this stage, the publicly available docket identifies the proceeding by the title Resmed Corp., but practitioners will want to monitor the case record closely as the petition, mandatory notices, and related filings further clarify the specific patent claims at issue, the identity of all real parties in interest, and any parallel district court or ITC litigation that may shape the Board’s discretionary-review analysis.

As with any newly filed IPR, the key issues will center on which patent is being challenged, which claims are targeted, and what prior-art grounds are asserted. Typically, petitioners rely on anticipation and obviousness grounds under 35 U.S.C. §§ 102 and 103, supported by combinations of patents, printed publications, and expert declarations.

A new inter partes review proceeding at the Patent Trial and Appeal Board could draw close attention from patent owners, challengers, and counsel following the medical technology sector. In IPR2026-00341, filed June 12, 2026, the petition is styled Resmed Corp., signaling that ResMed is involved in a fresh PTAB dispute over the validity of an issued patent.

At this early stage, the public docket identifies the proceeding but may not yet fully reflect all underlying petition details, including the specific patent number, all real parties in interest, and the complete list of asserted prior-art grounds.